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A systematic review and meta-analysis of
erythropoietin in experimental stroke
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Victoria E O’Collins3, Thomas Linden1, Michael Nilsson1 and David W Howells3
1Department of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; 2Department
of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK; 3Department of Medicine, University of
Melbourne and National Stroke Research Institute, Melbourne, Victoria, Australia
Erythropoietin (EPO) has shown promise as a neuroprotectant in animal models of ischemic stroke.
EPO is thought not only to protect neurons from cell death, but also to promote regeneration after
stroke. Here, we report a systematic review and meta-analysis of the efficacy of EPO in animal
models of focal cerebral ischemia. Primary outcomes were infarct size and neurobehavioral
outcome. Nineteen studies involving 346 animals for infarct size and 425 animals for neurobeha-
vioral outcome met our inclusion criteria. Erythropoietin improved infarct size by 30.0% (95% CI:
21.3 to 38.8) and neurobehavioral outcome by 39.8% (33.7 to 45.9). Studies that randomized to
treatment group or that blinded assessment of outcome showed lower efficacy. Erythropoietin was
tested in animals with hypertension in no studies reporting infarct size and in 7.5% of the animals
reporting neurobehavioral outcome. These findings show efficacy for EPO in experimental stroke,
but when the impact of common sources of bias are considered, this efficacy falls, suggesting we
may be overestimating its potential benefit. As common human co-morbidities may reduce
therapeutic efficacy, broader testing to delineate the range of circumstances in which EPO works
best would be beneficial.
Journal of Cerebral Blood Flow & Metabolism (2010) 30, 961–968; doi:10.1038/jcbfm.2009.267; published online
30 December 2009
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Introduction
Of hundreds of interventions that improve outcome
in experimental stroke, only recombinant tissue
plasminogen activator has found a place in routine
clinical practice (O’Collins et al, 2006). This dis-
crepancy between animal and human studies might
be due to bias in the conduct or reporting of animal
experiments leading to an overstatement of neuro-
protective efficacy; to a failure of clinical trials to test
interventions under circumstances where efficacy
has been observed in animals; or to a failure of
animal studies to model human diseases with
sufficient fidelity. Systematic review and meta-
analyses are techniques that allow an assessment
of the likelihood that research conclusions are
distorted by bias, and a clear description of
the circumstances under which efficacy has been
observed in animals.
Erythropoietin is a hematopoietic growth factor used
clinically to treat anemia, which has shown promise as
an acute treatment in in vitro and in vivo studies in
cerebral ischemia (Ruscher et al, 2002; Sinor and
Greenberg, 2000; Siren et al, 2001). The mechanisms
of this reported protection are not clear, but may
include activation of endogenous survival pathways
that inhibit apoptosis (Fliser et al, 2006) and decrease
inflammatory responses (Villa et al, 2003). Erythropoie-
tin has also been shown to support regeneration by
recruiting stem cells and stimulating neoangiogenesis
(Brines and Cerami, 2008). To date, the single published
clinical trial of EPO in acute ischemic stroke showed
limited success in its results (Ehrenreich et al, 2002),
the Multicenter-Erythropoietin-Stroke Trial is awaiting
analysis and the REGENESIS study (of EPO with
recombinant human chorionic gonadotrophin) is in
follow-up. The benefits of EPO in human stroke are
therefore not known at the present time.
Here, we report a systematic review and meta-
analysis of the use of EPO in experimental stroke.
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Our aim was to investigate whether elements of
study design or quality have a significant impact on
outcome. These data may assist the development of
further preclinical hypothesis to test in animals and
in the design of future large-scale clinical trials.
Materials and methods
Systematic Review
We searched three electronic databases (Pubmed, ISI Web
of Science, and Embase, in July 2009) using the terms (EPO
or erythropoietin) and (stroke or ischemia or ischaemia or
cerebrovascular or middle cerebral artery or MCA or
MCAO or ACA or ACAO or anterior cerebral artery),
limiting results to animals.
Two investigators (MJ, KF) assessed the titles and
abstracts of studies and obtained copies of articles that
described controlled studies of EPO or EPO analogues in
animal models of focal cerebral ischemia and that
measured outcome as infarct size or neurobehavioral
outcome. The latter was defined to include all methods
measuring neurobehavioral outcome or functional beha-
vior where a baseline of normal or pre-stroke function
could be clearly established. Articles in foreign languages
were translated. Reference lists of the articles were
assessed to locate additional studies not identified in the
initial search.
Data Extraction
From included studies, we extracted data on study design
including method of ischemia induction, species, dose,
time and route of administration, and time of assessment of
outcome. The number of animals used, mean and variance
of treatment and control groups were also extracted. Where
data required for meta-analysis were missing, we contacted
authors to request additional information. If data were only
expressed graphically, values were requested from the
authors, and where a response was not received, we
measured data from the graphs using digital ruler software.
Where data required for meta-analysis were not presented
or obtainable, the studies were excluded from the analysis.
Study quality was assessed based on the CAMARADES
study quality checklist (Macleod et al, 2004) comprising (1)
publication in a peer-reviewed journal, (2) statement of
control of temperature, (3) statement of monitoring of
physiologic parameters, (4) randomization to treatment or
control, (5) blinded induction of ischemia, (6) blinded
assessment of outcome, (7) anesthetic without marked
intrinsic neuroprotective properties, (8) use of co-morbid
animals (9) sample size calculation, (10) statement of
compliance with animal welfare regulations, and (11) state-
ment regarding possible conflicts of interest.
Statistical Analysis
A random effects weighted mean difference meta-analysis
was used for statistical analysis (DerSimonian and Laird,
1986). The data were stratified according to elements of
study quality and aspects of study design to assess their
impact on efficacy. We assessed the impact of continuous
variables (dose, time of administration, and assessment) on
the efficacy of EPO using meta-regression. To allow for
multiple comparisons, we set our significance level using
Bonferroni correction; P<0.003 for both infarct volume
and neurobehavioral outcome.
Results
Our search identified 1565 unique publications of
which 19 met our inclusion criteria and were
included in this analysis (Tables 1–3). One publica-
tion was excluded from the analysis because the
results were not presented in figures or graphs and
another publication was excluded because the
number of animals used was not stated (Chang
et al, 2008; Yu et al, 2005). In both circumstances,
we were unable to obtain this information from the
authors.
For treatment initiated after induction of ischemia,
infarct volume was reported in 23 experiments using
346 animals and neurobehavioral outcome was re-
ported in 30 experiments using 425 animals. For
treatment initiated before induction of ischemia, infarct
volume was reported in 6 experiments using 109
animals and neurobehavioral outcome was not studied.
Overall Efficacy and Impact of Study Design
Erythropoietin and EPO analogues improved infarct
volume by 30.0% (95% CI: 21.3 to 38.8) and
neurobehavioral outcome by 39.8% (33.7 to 45.9).
There was substantial between-study heterogeneity
for the analysis of both infarct volume (w2 = 63.5,
df = 22, P<0.003) and neurobehavioral outcome
(w2 = 67.5, df = 29, P<0.003).
For infarct volume, meta-regression suggested that
efficacy was reduced by 0.90% (0.39 to 1.41,
P<0.003) per hour of delay in treatment, and efficacy
was reduced by 2.41% (1.51 to 3.51, P<0.003) per
hour of later assessment. No relationship was
identified for neurobehavioral outcome.
For infarct volume, efficacy was highest when EPO
was administered once rather than multiple times
(41.6% (32.9% to 50.2%), w2 = 33.9, df = 1, P<0.003;
Figure 1A) and when the method of middle cerebral
artery occlusion was not stated (48.0% (41.3% to
54.6%), w2 = 35.4, df = 5, P<0.003; Figure 1B).
For neurobehavioral outcome, efficacy was highest
with continuous infusion of EPO rather than single
or multiple injections (55.3% (21.1% to 89.4%),
w2 = 26.7, df = 2, P<0.003; Figure 1C); when the
method of middle cerebral artery occlusion was not
stated (68.8% (26.8% to 110.9%), w2 = 28.9, df = 5,
P<0.003; Figure 1D) and in permanent rather than
temporary or thromboembolic models of ischemia
(49.1% (41.0% to 57.2%) w2 = 18.0, df = 2, P<0.003;
Figure 1E).
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A separate meta-analysis of the efficacy of the eight
experiments using EPO analogues only was also
performed (Table 2). Infarct volume was reported in 8
experiments using 116 animals and neurobehavioral
outcome was reported in 8 experiments using 114
animals. Erythropoietin analogues improved infarct
volume by 45.4% (38.7 to 52.2, w2 = 8.11, df = 7,
P=ns) and neurobehavioral outcome by 49.4% (40.5
to 58.3, w2 = 11.0, df = 7, P=ns).
For treatment initiated before induction of ischemia,
EPO improved infarct volume by 33.8% (18.2 to 49.5,
w2 =19.5 df=5, P<0.003). Efficacy was highest when
EPO was administered once rather than multiple times
(50.6% (35.7 to 65.4), w2 =9.5, df=1, P<0.003).
Impact of Study Quality
Overall, studies had a median quality score of 4 out
of 11 for both outcomes (interquartile range 3 to 5).
Study quality accounted for a significant amount of
between-study heterogeneity; for infarct volume,
studies that reported random allocation to group
were associated with lower estimates of efficacy than
those that did not (18.7% (10.3 to 27.1, n=146
animals) versus 36.4% (25.6% to 47.2%, n=195),
w2 = 19.7, df = 1, P<0.003; Figure 2A). Neurobeha-
vioral outcome studies that reported blinded assess-
ment of outcome were associated with lower
estimates of efficacy (30.8% (23.7% to 38.0%,
n=211) versus 47.3% (40.3% to 54.4%, n=186),
w2 = 24.3, df = 1, P<0.003; Figure 2B). Hypertensive
animals were only used in studies assessing neuro-
behavioral outcome (32 animals out of 425), and
there was no difference in efficacy between these
groups. Significant differences between high and low
quality studies were observed, with low quality
studies reporting the highest efficacy for both out-
comes (P<0.003; Figures 3A and 3B).
Discussion
Our analysis of 18 publications identified a signifi-
cant improvement in experimental stroke after EPO
Table 1 Studies describing the use of EPO administered after induction of focal cerebral ischemia
Author, year of
publication
Drug Species Stroke model Method of administration Outcome measures,
n (treated/control)
Quality
score
Sadamoto et al
(1998)
EPO Rat Permanent
MCAO
Immediately after occlusion,
intracerebroventricular infusion,
0.73, 3.64, or 18.18U/kg daily
for 28 days
Morris water maze (24/8) 6
Brines et al
(2000)
EPO Rat Permanent
MCAO
Immediately, 3, 6, or 9 h after
occlusion, intraperitoneal
injection, 5,000U/kg
Infarct volume (32/9) 4
Dahlberg et al
(2004)
EPO Rat MCAO (2h) 5mins after occlusion,
intraperitoneal injection,
5,000U/kg
Infarct volume (10/10) 3
Wang et al
(2004)
EPO Rat Embolic
MCAO
24h after occlusion,
intraperitoneal injection,
5,000 or 10,000U/kg
Infarct volume (16/8)
Foot Fault test (28/14)
Corner test (28/14)
3
Faure et al
(2006)
EPO Gerbil Permanent
CCAO
2 and 48h after occlusion,
intraperitoneal injection,
5,000U/kg
Morris water maze (19/6)
Object recognition (19/6)
5
Aluclu et al
(2007)
EPO Rat MCAO (2h) 2h after occlusion,
intraperitoneal injection,
5,000U/kg
Neurological score (15/15) 3
Kolb et al
(2007)
EPO Rat Permanent focal
devascularization
72h after occlusion,
intracerebroventricular infusion
for 7 days, total 927U/kg
Cylinder test (6/15)
Swimming task (6/15)
Tray reaching test (6/15)
3
Villa et al
(2007)
EPO Rat Permanent
MCAO
3h after occlusion, intravenous
injection, 5,000U/kg
De Ryck somatosensory
score (7/7)
Foot-fault test (7/7)
3
Wang et al
(2007)
EPO Rat Embolic
MCAO
6, 24, and 48h after occlusion,
intravenous injection, 50, 500,
1150, or 5,000U/kg
Infarct volume (36/12)
Foot-fault test (40/10)
4
Esneault et al
(2008)
EPO Rat MCAO (1.5h) 24 and 48h after occlusion,
intraperitoneal injection,
1,000U/kg per injection
Infarct volume (10/12)
Neurological score (10/12)
Limb placing (10/12)
5
Belayev et al
(2009)
EPO Rat MCAO (1.5h) 6, 7, and 8 days after occlusion,
intravenous injection,
1,440U/kg per injection
Infarct volume (12/13)
Neurological score (12/13)
7
Fletcher et al
(2009)
EPO Mouse MCAO (1h) Immediately after occlusion,
intranasal, 100U
Infarct volume (16/16)
Neurological score (16/16)
6
Li et al (2009) EPO Rat Embolic
MCAO
24h after occlusion and then
daily for 7 days, intraperitoneal
injection, 5,000U/kg
Infarct volume (11/7)
Neurological score (11/7)
5
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treatment. However, these results must be inter-
preted with caution due to potential sources of bias,
such as the lack of allocation concealment and
randomization to group of some of the included
studies.
Erythropoietin was most effective the earlier it was
administered after ischemic stroke induction,
although efficacy is still maintained up to treatment
initiation of 24 h post-ischemia. This supports the
hypothesis that EPO not only has neuroprotective
properties but may also support regeneration.
There are limited data using EPO in animals with
co-morbidities associated with human stroke; only
7.5% of the animals in the neurobehavioral dataset
were hypertensive, all of which were spontaneously
hypertensive rats. The efficacy of EPO in the
presence of such co-morbidities may have implica-
tions for the potential use of EPO in stroke patients.
Table 2 Studies describing the use of EPO analogues administered after induction of focal cerebral ischemia
Author,
year of
publication
Drug Species Stroke model Method of administration Outcome measures,
n (treated/control)
Quality
score
Erbayraktar
et al (2003)
Asialo EPO Rat MCAO (1.5h) 1.5 h after occlusion,
intravenous injection,
44 mg/kg
Infarct volume (6/6) 4
Leist et al
(2004)
Carbamylated EPO Rat MCAO (1h) 1 or 4h after occlusion,
intravenous injection,
5 or 50mg/kg
Infarct volume (8/16
and 8/8)
1
Belayev
et al (2005)
Darepoetin alfa Rat MCAO (2h) 2h after occlusion,
intraperitoneal injection,
10 mg/kg
Infarct volume (16/13)
Limb placing (16/13)
7
Villa et al
(2007)
Caranesp Rat Permanent
MCAO
1h after occlusion,
intravenous injection,
50 mg/kg
Infarct volume (9/9)
De Ryck somatosensory
score (9/9)
3
Carbamylated EPO Rat Permanent
MCAO
1h after occlusion,
intravenous injection,
50 mg/kg
Infarct volume (8/9)
De Ryck somatosensory
score (8/9)
3
Carbamylated EPO Rat Permanent
MCAO
3 or 3, 24, and 48h after
occlusion, intravenous
injection, 50mg/kg per
injection
De Ryck somatosensory
score (5/7 and 5/7)
Foot fault (5/7 and 5/7)
3
Carbamylated EPO Rat Permanent
MCAO
24 and 48h after occlusion,
intravenous injection,
50 mg/kg per injection
De Ryck somatosensory
score (5/5)
Foot fault (5/5)
3
EPO S-100E Rat Permanent
MCAO
3h after occlusion,
intravenous injection,
50 mg/kg
De Ryck somatosensory
score (8/8)
3
Table 3 Studies describing the use of EPO administered before induction of focal cerebral ischemia
Author,
year of publication
Drug Species Stroke model Method of administration Outcome measures,
n (treated/control)
Quality
score
Bernaudin
et al (1999)
EPO Mouse MCAO (1.5h) 24h before occlusion,
intracerebroventricular
infusion, 50U/kg
Infarct volume (8/9) 3
Brines et al
(2000)
EPO Rat Permanent
MCAO
24h before occlusion,
intraperitoneal injection,
5,000U/kg
Infarct volume (8/9) 4
Dahlberg et al
(2004)
EPO Rat MCAO (2h) Immediately before
occlusion and then once
daily for 7 days,
subcutaneous injection,
5,000U/kg
Infarct volume (11/10) 3
Li et al (2007) EPO Mouse Permanent
MCAO
0.5h before occlusion
and then once daily,
intraperitoneal injection,
5,000U/kg
Infarct volume (6/6) 5
Wakida et al
(2007)
EPO Mouse Permanent
MCAO
24 and 1h before and
immediately after occlusion,
intraperitoneal injection,
30,000U/kg per injection
Infarct volume (11/13
and 7/11)
5
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Figure 1 Effect on the estimate of efficacy for infarct volume of (A) type of delivery, (B) method of artery occlusion, and for
neurobehavioral outcome of (C) type of delivery, (D) method of artery occlusion, and (E) model of ischemia, P<0.003. The shaded
gray bar represents the 95% confidence limits of the global estimate. The vertical error bars represent the 95% confidence intervals
for the individual estimates. The width of each bar reflects the log of the number of animals contributing to that comparison.
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This review is subject to possible methodological
weaknesses. First, the dataset is too small to reliably
assess publication bias. In a review of seven different
growth factors including EPO (unpublished data),
publication bias was identified using a funnel plot
and Egger regression, and it is reasonable to expect
that this bias extends to these data. Second, analysis
can only include data described in the identified
articles. This might relate not only to the reporting of
items described in the CAMARADES quality check-
list (although recent guidelines now recommend this
(Macleod et al, 2009), but also incomplete presenta-
tion of data, for instance of efficacy at later time
points or at lower doses.
This study is a comprehensive systematic review
of the use of EPO therapies in experimental stroke.
The only clinical trial published to date reported that
EPO did not significantly affect stroke mortality,
although it did report improvements in functional
outcome on the Barthel Index and beneficial trends
on the NIH and Scandinavian stroke scales as well as
on infarct size as a secondary outcome. The limited
animal and human data on the safety and efficacy of
EPO in ischemic stroke suggests further testing of
EPO in experimental models is warranted before
further clinical trials. Elucidating the conditions in
which the most benefit is seen in studies with
minimal potential sources of bias may provide
potential hypotheses to test in clinical trials.
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